行情

GHDX

GHDX

基因组健康
NASDAQ

实时行情|Nasdaq Last Sale

63.44
0.00
0.00%
已退市 09:30 12/13 EST
开盘
63.88
昨收
63.88
最高
64.57
最低
62.74
成交量
1,253.71万
成交额
--
52周最高
86.70
52周最低
50.77
市值
23.85亿
市盈率(TTM)
43.05
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GHDX 新闻

  • Celgene (CELG) Hits 52-Week High, Can the Run Continue?
  • Zacks.11/11 14:15
  • Exact Sciences completes $2.8B acquisition of Genomic Health
  • American City Business Journals.11/08 17:22
  • Why the Earnings Surprise Streak Could Continue for Genomic Health (GHDX)
  • Zacks.11/08 15:10
  • Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
  • PR Newswire.11/08 13:02

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

GHDX 简况

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.
展开

Webull提供Genomic Health, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。